JP2021522255A5 - - Google Patents
Info
- Publication number
- JP2021522255A5 JP2021522255A5 JP2020559529A JP2020559529A JP2021522255A5 JP 2021522255 A5 JP2021522255 A5 JP 2021522255A5 JP 2020559529 A JP2020559529 A JP 2020559529A JP 2020559529 A JP2020559529 A JP 2020559529A JP 2021522255 A5 JP2021522255 A5 JP 2021522255A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- formula
- constipation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662574P | 2018-04-25 | 2018-04-25 | |
| US62/662,574 | 2018-04-25 | ||
| PCT/US2019/029219 WO2019210103A2 (en) | 2018-04-25 | 2019-04-25 | Slc26a3 inhibitors and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522255A JP2021522255A (ja) | 2021-08-30 |
| JP2021522255A5 true JP2021522255A5 (enExample) | 2022-05-09 |
| JP7442824B2 JP7442824B2 (ja) | 2024-03-05 |
Family
ID=67439317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559529A Active JP7442824B2 (ja) | 2018-04-25 | 2019-04-25 | Ｓｌｃ２６ａ３阻害剤及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11591304B2 (enExample) |
| EP (1) | EP3784229A2 (enExample) |
| JP (1) | JP7442824B2 (enExample) |
| AU (1) | AU2019257722B2 (enExample) |
| CA (1) | CA3098293A1 (enExample) |
| WO (1) | WO2019210103A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102019005196A1 (de) * | 2019-07-25 | 2021-01-28 | Forschungszentrum Jülich GmbH | Verfahren zur Herstellung eines Cumarin-caged Forskolinderivats, Forskolinderivat und Verwendung des Forskolinderivats |
| US20250073242A1 (en) | 2021-07-30 | 2025-03-06 | The Regents Of The University Of California | Slc26a3 inhibitors and use thereof |
| WO2023081967A1 (en) * | 2021-11-10 | 2023-05-19 | The University Of Western Australia | Compounds and uses therefor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101362722B (zh) * | 2008-09-27 | 2011-04-27 | 山东大学 | N-取代苯基-2-(1-芳基-1h-咪唑-2-巯基)乙酰胺类衍生物及其制备方法与应用 |
| WO2010056914A1 (en) | 2008-11-12 | 2010-05-20 | Microbiotix, Inc. | Bacterial helicase inhibitor compounds and uses thereof |
| WO2017147523A1 (en) | 2016-02-26 | 2017-08-31 | The Regents Of The University Of California | Small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions |
-
2019
- 2019-04-25 CA CA3098293A patent/CA3098293A1/en active Pending
- 2019-04-25 WO PCT/US2019/029219 patent/WO2019210103A2/en not_active Ceased
- 2019-04-25 AU AU2019257722A patent/AU2019257722B2/en active Active
- 2019-04-25 US US17/050,393 patent/US11591304B2/en active Active
- 2019-04-25 EP EP19744904.4A patent/EP3784229A2/en active Pending
- 2019-04-25 JP JP2020559529A patent/JP7442824B2/ja active Active
-
2023
- 2023-01-18 US US18/156,333 patent/US12187694B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6012639B2 (ja) | 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 | |
| JP2023002662A5 (enExample) | ||
| CA3018132C (en) | Use of elafibranor in the treatment of a cholestatic disease | |
| JPWO2023054292A5 (enExample) | ||
| TW201733583A (zh) | Fxr促效劑之使用方法 | |
| JP2020514352A (ja) | 組合せ療法のための医薬組成物 | |
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| JP2017526716A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2017530163A5 (enExample) | ||
| JP2024541569A5 (enExample) | ||
| JP2022511788A5 (enExample) | ||
| EA201401042A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| CN115227826A (zh) | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 | |
| JP6915050B2 (ja) | Ｆｘｒアゴニストの新規のレジーム | |
| JPWO2009096455A1 (ja) | 脂肪性肝疾患の治療用医薬組成物 | |
| JP2023549849A5 (enExample) | ||
| JP2008534592A5 (enExample) | ||
| JP2022517902A5 (enExample) | ||
| EP3512558A1 (en) | Combination of fxr agonists | |
| RU2007107935A (ru) | Полисульфатированные гликозиды и их соли | |
| CN107206002A (zh) | 尿酸性或痛风性疾病的预防或治疗 | |
| CN102892760B (zh) | 非醇性脂肪性肝炎的预防和/或治疗剂 |